Please ensure Javascript is enabled for purposes of website accessibility

Amgen Pauses Some Clinical Trials to Reduce Coronavirus Transmission Risk

By Cory Renauer - Mar 31, 2020 at 1:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The COVID-19 pandemic has led the big biotech to join many of its peers in making timeline-altering drug study adjustments.

In their efforts to reduce the chances of people being exposed to COVID-19, a growing number of medical centers around the globe have started restricting nonessential visits, including those necessary to conduct clinical drug trials.

In light of that, and to avoid unnecessary risks, biotechnology giant Amgen (AMGN -0.30%) recently decided to pause enrollment and screening of clinical trials wherever safety and data integrity could become an issue. 

In a recent update regarding its COVID-19 pandemic strategy, Amgen outlined the basic principles that will guide its drug development activity over the next several months. Studies of treatments that could provide evidence of a life-saving benefit to patients who lack other options will continue as long as registered trial sites can safely enroll and monitor patients. 

Doctor in personal protective equipment.

Image source: Getty Images.

Patients already enrolled in trials will continue to receive drugs being studied, and Amgen thinks its most important late-stage trials will complete without disruption. A potentially pivotal phase 2 lung cancer study of AMG 510 is already fully enrolled, as are phase 3 studies of a potential new asthma treatment called tezepelumab and a heart failure candidate called omecamtiv mecarbil.

At the moment, Amgen has 22 experimental treatments for cancer, cardiovascular disease, obesity, and inflammation in phase 1 trials. Since these are mostly first attempts to gauge a drug candidate's safety and potential toxicity at various dosages, those studies will probably be delayed indefinitely. 

Patients relying on Amgen drugs that have already been tested shouldn't have to worry about shortages. The company says it doesn't expect any interruption to its supply of approved medicines.  

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
$246.25 (-0.30%) $0.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.